United Therapeutics (NASDAQ:UTHR) Raised to Strong-Buy at StockNews.com

United Therapeutics (NASDAQ:UTHR - Get Free Report) was upgraded by investment analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Thursday.

Other analysts have also issued research reports about the stock. HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a report on Thursday, October 31st. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Finally, Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $378.36.

United Therapeutics Price Performance

Shares of UTHR stock traded up $4.75 during trading hours on Thursday, hitting $366.39. 255,042 shares of the company's stock were exchanged, compared to its average volume of 262,894. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $417.82. The stock has a market cap of $16.36 billion, a price-to-earnings ratio of 16.09, a price-to-earnings-growth ratio of 0.93 and a beta of 0.57. The stock's 50-day moving average is $369.14 and its 200-day moving average is $353.37.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.38 EPS. Equities research analysts forecast that United Therapeutics will post 25.22 earnings per share for the current fiscal year.

Insider Activity

In other United Therapeutics news, CFO James Edgemond sold 7,782 shares of the business's stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the transaction, the chief financial officer now directly owns 6,426 shares of the company's stock, valued at approximately $2,358,277.74. The trade was a 54.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher Causey sold 510 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company's stock, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 144,630 shares of company stock valued at $54,371,916 in the last quarter. Company insiders own 11.90% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. USA Financial Formulas acquired a new stake in United Therapeutics in the 3rd quarter valued at approximately $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $82,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in United Therapeutics during the third quarter worth about $90,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.